Iversuvac 12 — Ivermectin 12 mg, 10 Tablets

Iversuvac-12 is supplied as white to off-white, uncoated, round tablets designed for oral administration. Supplied per individual blister strip:

• Packaging Configuration: 1 blister strip (plate) = 10 tablets.
• Active Ingredient: Ivermectin (Ivermectin IP) — 12 mg per tablet.
• Inactive Excipients: Microcrystalline cellulose (binder/diluent), maize starch, magnesium stearate (lubricant), purified talc, sodium starch glycolate (disintegrant ensuring prompt dissolution).

Pharmacodynamics: Ivermectin is a semi-synthetic derivative belonging to the avermectin class of macrocyclic lactones derived from Streptomyces avermitilis. It binds selectively and with high affinity to glutamate-gated chloride channels in invertebrate muscle and nerve cells. The resulting influx of chloride ions leads to membrane hyperpolarization, neuromuscular blockage, flaccid paralysis, and parasite death. Ivermectin also enhances gamma-aminobutyric acid (GABA) release at presynaptic inhibitory synapses.

Pharmacokinetics: Following oral administration, Ivermectin is rapidly absorbed from the gastrointestinal tract. Peak plasma levels (Cmax of approximately 46 mcg/L following a 12 mg dose) are achieved in about 4 hours. It is highly bound to plasma proteins (approximately 99%). Ivermectin is extensively metabolized in the liver by cytochrome P450 enzymes (specifically CYP3A4) into inactive metabolites. The terminal plasma elimination half-life (T1/2) ranges from 12 to 18 hours. Elimination is predominantly via feces (over 12 days) as metabolites and unchanged drug; less than 1% is excreted in urine.

Iversuvac-12 is indicated for the medical management of the following parasitic infestations:

• 🔹 Strongyloidiasis: Intestinal infection caused by the threadworm parasite Strongyloides stercoralis.
• 🔹 Onchocerciasis: Known as "river blindness", caused by the filarial worm Onchocerca volvulus.
• 🔹 Lymphatic Filariasis: As part of combination therapy to clear microfilariae caused by Wuchereria bancrofti or Brugia malayi.
• 🔹 Intestinal Nematodiases: Infections caused by Ascaris lumbricoides (ascariasis), Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), and hookworms.
• 🔹 Ectoparasitic Conditions: Scabies (including severe crusted/Norwegian scabies), demodicosis, and pediculosis as directed by a healthcare provider.

Iversuvac-12 tablets are formulated strictly for oral administration. Precise dosage and regimen must be determined by a physician based on body weight and clinical diagnosis:

• 💊 Standard Dosage Calculation: Dosing is calculated at 150–200 mcg of Ivermectin per kg of body weight. For an average adult weighing between 50 kg and 80 kg, the standard single dose is 1 tablet (12 mg). For patients exceeding 80 kg, 1.5 to 2 tablets may be prescribed.
• ⏱️ Administration Protocol: Take tablets strictly on an empty stomach with a full glass of water (200 mL), either 1 hour before a meal or 2 hours after eating.
• 🍽️ Impact of Food: Co-ingestion with high-fat meals increases systemic bioavailability and plasma AUC by nearly 2.5-fold, which may increase the risk of systemic adverse effects. Strict adherence to empty-stomach dosing is mandatory.
• 🚫 Treatment Course: A single dose is usually sufficient for strongyloidiasis and intestinal worms. For onchocerciasis, retreatment every 6 to 12 months is required. For scabies or demodicosis, a second dose 7 to 14 days later is frequently indicated to eradicate newly hatched mites.

Iversuvac-12 is strictly contraindicated in patients presenting with any of the following medical factors:

• ❌ Hypersensitivity or known allergic reaction to Ivermectin or any of the inactive excipients in the formulation.
• ❌ Compromised blood-brain barrier integrity or central nervous system disorders characterized by increased BBB permeability (e.g., meningitis, trypanosomiasis).
• ❌ Pregnancy (all trimesters) and breastfeeding (lactation period).
• ❌ Pediatric patients weighing less than 15 kg (safety and efficacy have not been established in this subgroup).
• ❌ Severe hepatic or renal impairment resulting in end-stage organ dysfunction.

Co-administration of Iversuvac-12 with other pharmaceuticals requires careful clinical evaluation:

• ⚠️ GABAergic Agents: Concomitant use with drugs that enhance GABA activity (e.g., benzodiazepines, barbiturates, valproic acid, baclofen) may potentiate central nervous system depression.
• ⚠️ Anticoagulants (e.g., Warfarin): Post-marketing cases have noted prolonged prothrombin time/INR when Ivermectin is co-administered with oral anticoagulants; INR monitoring is recommended.
• ⚠️ P-glycoprotein and CYP3A4 Modulators: Potent CYP3A4 or P-gp inhibitors (e.g., ketoconazole, erythromycin) may increase plasma concentrations of Ivermectin, while inducers (e.g., rifampicin, St. John's wort) may decrease efficacy.

Iversuvac-12 is **contraindicated during pregnancy**. Animal reproduction studies have demonstrated teratogenic risks associated with Ivermectin exposure. Women of childbearing potential should confirm non-pregnant status prior to initiating therapy. Ivermectin is excreted in human breast milk in low concentrations. Breastfeeding should be suspended during treatment and should not be resumed for at least 7 days following the last administered dose.

Iversuvac-12 is generally well tolerated. Most reported adverse effects are mild to moderate in intensity and are frequently attributed to host inflammatory responses to dying microfilariae or parasites (Mazzotti reaction) rather than direct drug toxicity:

• 💆 Central Nervous System: Dizziness, somnolence, lightheadedness, mild headache, peripheral tremor, vertigo.
• 🤢 Gastrointestinal: Nausea, vomiting, abdominal pain or epigastric discomfort, diarrhea, transient anorexia.
• 🧴 Dermatological & Allergic: Pruritus, papular or maculopapular rash, urticaria, localized edema, lymphadenopathy (tender/swollen lymph nodes).
• 🦴 Musculoskeletal: Arthralgia (joint pain), myalgia (muscle aches).
• 👁️ Ophthalmological (primarily in onchocerciasis): Conjunctivitis, ocular burning sensation, eyelid edema, transient blurred vision.

Overdose Symptoms: Accidental or intentional ingestion of excessive doses amplifies known pharmacological adverse effects. Symptoms include severe rash, urticaria, facial and limb edema, intense headache, dizziness, asthenia, persistent nausea and vomiting, ataxia, paresthesia, and in severe cases, altered mental status, seizures, coma, and respiratory depression.

Overdose Management: Immediate medical attention is mandatory. Treatment consists of gastric lavage, administration of activated charcoal or enterosorbents, and saline cathartics. Supportive therapy should focus on maintaining airway patency, oxygenation, and hemodynamics. No specific antidote exists. Hemodialysis is ineffective due to high plasma protein binding.

Storage guidelines for Iversuvac-12 blister strips:

• 🌡️ Temperature: Store in a dry, cool place protected from direct sunlight and moisture at a temperature below 30 °C.
• 💧 Packaging Protection: Retain tablets inside the original aluminum foil blister packaging until immediately prior to administration.
• 👶 Child Safety: Keep strictly out of reach and sight of children and pets.
• ⏳ Shelf Life: The shelf life is 3 years from the date of manufacture. The batch number, manufacturing date, and expiry date are deeply embossed on the edge of each blister strip. Do not use after the expiration date.

To verify the authenticity of your Iversuvac-12 blister strip and protect against counterfeit products, inspect the following physical details:

• 🛡️ Foil Printing Quality: The metallic backing foil features sharp, high-definition printing containing the Medsuvac company logo, product name Iversuvac-12, and composition details (Ivermectin Tablets IP 12 mg).
• 🔍 Embossed Manufacturing Markings: The sealed outer margin of each blister strip features clear, deeply stamped indentations showing the Batch Number (Batch No.), Manufacturing Date (Mfg. Date), and Expiry Date (Exp. Date).
• 📦 Physical Tablet Attributes: Tablets are uniform white, round, uncoated, and free of chipping, discoloration, or crumbling. The blister pockets are securely heat-sealed and airtight.